Scottish epilepsy patients as young as two could be given new cannabis-based medication today approved for use on the NHS. Health bosses have given the green light to Epidyolex, which can help treat the symptoms of a rare genetic disease affecting around one in 10,000 people. Tuberous sclerosis complex (TSC) causes tumors to grow in the body and around 80% of patients develop epilepsy from it, typically in their first year of life. Additionally, for the majority of people, their condition doesn’t respond to standard anti-seizure medication – making today’s Scottish Medical Consortium decision a potential game-changer. Scotland has become the second UK nation to approve the oral solution for use, following Wales. Medication ‘desperately needed’ for families Louise Fish, the chief executive of the Tuberous Sclerosis Association, says life could now be very different for those with the debilitating condition. “TSC is often difficult to manage condition… and up to 60% of people with TSC-related epilepsy do not respond to standard anti-seizure medication,” she said. “New treatment options are desperately needed, and we are delighted that this medicine will now be available on the NHS for eligible patients in Scotland.

420 Intel – Marijuana Industry News, 02/06/2022 19:00:00

Open article: